| Order number | Description | Quantity | Delivery time | CE |
|---|---|---|---|---|
| PB CCLP-10 | Lupus Positive Multi Donor Plasma | 25x1 ml | 7-10 days | x |
Lupus Positive Multi Donor PlasmaCRYOcheck Lupus Positive Control is prepared from human source plasma and is recommended for use as a positive control in assays for lupus anticoagulant. An association between circulating anticoagulants and systemic lupus erythematosus (SLE) was first described in 1952. In 1972 the term “lupus anticoagulant” (LA) was used to describe these non-specific, circulating inhibitors. The designation LA is still used today although it is now evident the majority of these patients do not suffer from SLE. The presence of LA has been increasingly associated with a variety of disorders such as unexplained thrombosis and recurrent fetal loss. LA are immunoglobulins, usually of the IgG, IgM or IgA classes, which are directed against anionic phospholipids or phospholipidplasma protein complexes causing interference with in vitro phospholipid dependent coagulation tests. LA are clinically distinct members of a broader group of antiphospholipid antibodies (APA) characterized by antigenic protein targets such as B2 glycoprotein 1 and prothrombin. APA include LA as well as anticardiolipin, antiphosphatidylserine, and antiphosphatidylethanolamine antibodies. The SSC Subcommittee for the Standardization of Lupus Anticoagulants has specified four diagnostic criteria for LA: |
Additional Documentation
|
Login